Announcements Trials
Browse Landscape

Phase

Phase 1/2 8Phase 2 5Phase 3 1

Status

Recruiting 8Completed 1

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Breast 2Tumor-Agnostic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 2Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29Capecitabine 27atezolizumab 26Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × patritumab deruxtecan × Clear all
NCT06596694 2026-06-01

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
180 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT07286149 2026-05-26

MK-3475-01F

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
190 enrolled
Thoracic

Lung Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
81 enrolled
Breast

Breast Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
450 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
50 enrolled
Tumor-Agnostic

Neoplasms

NCT06298084 2024-03-29

ICARUSBREAST02

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
152 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡